Abstract
The loss of tumour phospho-extracellular responsive kinase (pERK) positivity is the major treatment biomarker for mitogen-activated protein kinase/extracellular responsive kinase (MEK) inhibitors. Here, we demonstrate that there is a poor correlation between pERK inhibition and the anti-proliferative effects of MEK inhibitors in melanoma cells. We suggest that Ki67 is a better biomarker for future clinical studies.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Biomarkers, Tumor / analysis*
-
Butadienes / analysis
-
Cell Line, Tumor
-
Cell Proliferation
-
Extracellular Signal-Regulated MAP Kinases / analysis*
-
Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors*
-
G1 Phase
-
Humans
-
Ki-67 Antigen / analysis*
-
Melanoma / drug therapy*
-
Melanoma / pathology
-
Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors*
-
Mutation
-
Nitriles / analysis
-
Phosphoinositide-3 Kinase Inhibitors
-
Phosphorylation
-
Proto-Oncogene Proteins B-raf / genetics
Substances
-
Biomarkers, Tumor
-
Butadienes
-
Ki-67 Antigen
-
Nitriles
-
Phosphoinositide-3 Kinase Inhibitors
-
U 0126
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf
-
Extracellular Signal-Regulated MAP Kinases
-
Mitogen-Activated Protein Kinase Kinases